Hikma’s group revenues jump 34.8%

DUBAI - Hikma Pharmaceuticals, the fast growing global pharmaceutical group, with sales in more than 50 countries across Europe, Mena and the USA, said its group revenue increased by 34.8 per cent to $532.3 million, with organic growth of 7.6 per cent.

Mazen Darwazah, chief executive officer of Mena and vice-chairman, said: “I expect the outlook to be positive for the second half of the year, and I am confident that the group will continue to perform well.”

More news from Local Business